ArticleDer Radiologe2021
[State of the art in the diagnostics of hepatocellular carcinoma and current treatment options].
Article in Der Radiologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- [Ablation of liver tumors : From pre-interventional imaging to post-interventional assessment].Radiologie (Heidelberg, Germany) · 2024Review
- [Small hepatocellular carcinoma : Diagnostics according to guidelines and established in the clinical setting].Der Radiologe · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary hepatic malignancy and arises most often based on liver cirrhosis. Of the HCC 80-85% demonstrate a typical contrast medium behavior in imaging, characterized by arterial hypervascularization followed by wash-out in the portal or late venous phase. This specific contrast behavior is diagnostic for HCC in patients at risk. The use of liver-specific contrast agents increases the sensitivity for diagnosis of HCC and can facilitate the differentiation from other liver lesions. At initial diagnosis approximately 50% of HCC are solitary, 40% multifocal and 10% diffuse. Depending on the tumor extent and stage, therapeutic options in patients with HCC include local treatment (resection, ablation, radiation, liver transplantation), locoregional measures (transarterial chemoembolization, selective internal radiotherapy) or systemic therapy (including immunotherapy), either as a stand-alone procedure or in various combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.